Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
A safe, effective, and scalable vaccine is urgently needed to halt the ongoing SARS-CoV-2 pandemic. Here, we describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly immunogenic array and induce neutralizing antibody titers roughly ten-fold higher than the prefusion-stabilized S ectodomain trimer despite a more than five-fold lower dose. Antibodies elicited by the nanoparticle immunogens target multiple distinct epitopes on the RBD, suggesting that they may not be easily susceptible to escape mutations, and exhibit a significantly lower binding:neutralizing ratio than convalescent human sera, which may minimize the risk of vaccine-associated enhanced respiratory disease. The high yield and stability of the protein components and assembled nanoparticles, especially compared to the SARS-CoV-2 prefusion-stabilized S trimer, suggest that manufacture of the nanoparticle vaccines will be highly scalable. These results highlight the utility of robust antigen display platforms for inducing potent neutralizing antibody responses and have launched cGMP manufacturing efforts to advance the lead RBD nanoparticle vaccine into the clinic.
| Errataetall: |
UpdateIn: Cell. 2020 Nov 25;183(5):1367-1382.e17. - PMID 33160446 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 12. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Walls, Alexandra C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Electronic UpdateIn: Cell. 2020 Nov 25;183(5):1367-1382.e17. - PMID 33160446 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.08.11.247395 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313917604 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313917604 | ||
| 003 | DE-627 | ||
| 005 | 20240216232057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.08.11.247395 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM313917604 | ||
| 035 | |a (NLM)32817941 | ||
| 035 | |a (PII)2020.08.11.247395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Walls, Alexandra C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Cell. 2020 Nov 25;183(5):1367-1382.e17. - PMID 33160446 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a A safe, effective, and scalable vaccine is urgently needed to halt the ongoing SARS-CoV-2 pandemic. Here, we describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly immunogenic array and induce neutralizing antibody titers roughly ten-fold higher than the prefusion-stabilized S ectodomain trimer despite a more than five-fold lower dose. Antibodies elicited by the nanoparticle immunogens target multiple distinct epitopes on the RBD, suggesting that they may not be easily susceptible to escape mutations, and exhibit a significantly lower binding:neutralizing ratio than convalescent human sera, which may minimize the risk of vaccine-associated enhanced respiratory disease. The high yield and stability of the protein components and assembled nanoparticles, especially compared to the SARS-CoV-2 prefusion-stabilized S trimer, suggest that manufacture of the nanoparticle vaccines will be highly scalable. These results highlight the utility of robust antigen display platforms for inducing potent neutralizing antibody responses and have launched cGMP manufacturing efforts to advance the lead RBD nanoparticle vaccine into the clinic | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Fiala, Brooke |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Wrenn, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Pham, Minh N |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Tse, Longping V |e verfasserin |4 aut | |
| 700 | 1 | |a Shehata, Laila |e verfasserin |4 aut | |
| 700 | 1 | |a O'Connor, Megan A |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Chengbo |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, Mary Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda, Marcos C |e verfasserin |4 aut | |
| 700 | 1 | |a Pettie, Deleah |e verfasserin |4 aut | |
| 700 | 1 | |a Ravichandran, Rashmi |e verfasserin |4 aut | |
| 700 | 1 | |a Kraft, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Ogohara, Cassandra |e verfasserin |4 aut | |
| 700 | 1 | |a Palser, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Chalk, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, E-Chiang |e verfasserin |4 aut | |
| 700 | 1 | |a Kepl, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, Cameron M |e verfasserin |4 aut | |
| 700 | 1 | |a Sydeman, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Hodge, Edgar A |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Brieann |e verfasserin |4 aut | |
| 700 | 1 | |a Fuller, Jim T |e verfasserin |4 aut | |
| 700 | 1 | |a Dinnon, Kenneth H |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Gralinski, Lisa E |e verfasserin |4 aut | |
| 700 | 1 | |a Leist, Sarah R |e verfasserin |4 aut | |
| 700 | 1 | |a Gully, Kendra L |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Thomas B |e verfasserin |4 aut | |
| 700 | 1 | |a Guttman, Miklos |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Helen Y |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Kelly K |e verfasserin |4 aut | |
| 700 | 1 | |a Fuller, Deborah H |e verfasserin |4 aut | |
| 700 | 1 | |a Baric, Ralph S |e verfasserin |4 aut | |
| 700 | 1 | |a Kellam, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Pepper, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Sheahan, Timothy P |e verfasserin |4 aut | |
| 700 | 1 | |a Veesler, David |e verfasserin |4 aut | |
| 700 | 1 | |a King, Neil P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 12. Aug. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:12 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.08.11.247395 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 12 |c 08 | ||